Adenoid cystic carcinoma

Current therapy and potential therapeutic advances based on genomic profiling

Young Kwang Chae*, Su Yun Chung, Andrew A. Davis, Benedito A Carneiro Filho, Sunandana Chandra, Jason B Kaplan, Aparna Kalyan, Francis Joseph Giles

*Corresponding author for this work

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Adenoid cystic carcinoma (ACC) is a rare cancer with high potential for recurrence and metastasis. Efficacy of current treatment options, particularly for advanced disease, is very limited. Recent whole genome and exome sequencing has dramatically improved our understanding of ACC pathogenesis. A balanced translocation resulting in the MYB-NFIB fusion gene appears to be a fundamental signature of ACC. In addition, sequencing has identified a number of other driver genes mutated in downstream pathways common to other well-studied cancers. Overexpression of oncogenic proteins involved in cell growth, adhesion, cell cycle regulation, and angiogenesis are also present in ACC. Collectively, studies have identified genes and proteins for targeted, mechanism-based, therapies based on tumor phenotypes, as opposed to nonspecific cytotoxic agents. In addition, although few studies in ACC currently exist, immunotherapy may also hold promise. Better genetic understanding will enable treatment with novel targeted agents and initial exploration of immune-based therapies with the goal of improving outcomes for patients with ACC.

Original languageEnglish (US)
Pages (from-to)37117-37134
Number of pages18
JournalOncotarget
Volume6
Issue number35
DOIs
StatePublished - Jan 1 2015

Fingerprint

Adenoid Cystic Carcinoma
Therapeutics
Exome
Neoplasms
Gene Fusion
Cytotoxins
Cell Adhesion
Immunotherapy
Cell Cycle
Proteins
Genome
Neoplasm Metastasis
Phenotype
Recurrence
Growth
Genes

Keywords

  • Adenoid cystic carcinoma
  • Genetics
  • Immunotherapy
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Chae, Young Kwang ; Chung, Su Yun ; Davis, Andrew A. ; Carneiro Filho, Benedito A ; Chandra, Sunandana ; Kaplan, Jason B ; Kalyan, Aparna ; Giles, Francis Joseph. / Adenoid cystic carcinoma : Current therapy and potential therapeutic advances based on genomic profiling. In: Oncotarget. 2015 ; Vol. 6, No. 35. pp. 37117-37134.
@article{31ae098e6d9e450d8011930bc73c2cbe,
title = "Adenoid cystic carcinoma: Current therapy and potential therapeutic advances based on genomic profiling",
abstract = "Adenoid cystic carcinoma (ACC) is a rare cancer with high potential for recurrence and metastasis. Efficacy of current treatment options, particularly for advanced disease, is very limited. Recent whole genome and exome sequencing has dramatically improved our understanding of ACC pathogenesis. A balanced translocation resulting in the MYB-NFIB fusion gene appears to be a fundamental signature of ACC. In addition, sequencing has identified a number of other driver genes mutated in downstream pathways common to other well-studied cancers. Overexpression of oncogenic proteins involved in cell growth, adhesion, cell cycle regulation, and angiogenesis are also present in ACC. Collectively, studies have identified genes and proteins for targeted, mechanism-based, therapies based on tumor phenotypes, as opposed to nonspecific cytotoxic agents. In addition, although few studies in ACC currently exist, immunotherapy may also hold promise. Better genetic understanding will enable treatment with novel targeted agents and initial exploration of immune-based therapies with the goal of improving outcomes for patients with ACC.",
keywords = "Adenoid cystic carcinoma, Genetics, Immunotherapy, Targeted therapy",
author = "Chae, {Young Kwang} and Chung, {Su Yun} and Davis, {Andrew A.} and {Carneiro Filho}, {Benedito A} and Sunandana Chandra and Kaplan, {Jason B} and Aparna Kalyan and Giles, {Francis Joseph}",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.5076",
language = "English (US)",
volume = "6",
pages = "37117--37134",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "35",

}

Adenoid cystic carcinoma : Current therapy and potential therapeutic advances based on genomic profiling. / Chae, Young Kwang; Chung, Su Yun; Davis, Andrew A.; Carneiro Filho, Benedito A; Chandra, Sunandana; Kaplan, Jason B; Kalyan, Aparna; Giles, Francis Joseph.

In: Oncotarget, Vol. 6, No. 35, 01.01.2015, p. 37117-37134.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adenoid cystic carcinoma

T2 - Current therapy and potential therapeutic advances based on genomic profiling

AU - Chae, Young Kwang

AU - Chung, Su Yun

AU - Davis, Andrew A.

AU - Carneiro Filho, Benedito A

AU - Chandra, Sunandana

AU - Kaplan, Jason B

AU - Kalyan, Aparna

AU - Giles, Francis Joseph

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Adenoid cystic carcinoma (ACC) is a rare cancer with high potential for recurrence and metastasis. Efficacy of current treatment options, particularly for advanced disease, is very limited. Recent whole genome and exome sequencing has dramatically improved our understanding of ACC pathogenesis. A balanced translocation resulting in the MYB-NFIB fusion gene appears to be a fundamental signature of ACC. In addition, sequencing has identified a number of other driver genes mutated in downstream pathways common to other well-studied cancers. Overexpression of oncogenic proteins involved in cell growth, adhesion, cell cycle regulation, and angiogenesis are also present in ACC. Collectively, studies have identified genes and proteins for targeted, mechanism-based, therapies based on tumor phenotypes, as opposed to nonspecific cytotoxic agents. In addition, although few studies in ACC currently exist, immunotherapy may also hold promise. Better genetic understanding will enable treatment with novel targeted agents and initial exploration of immune-based therapies with the goal of improving outcomes for patients with ACC.

AB - Adenoid cystic carcinoma (ACC) is a rare cancer with high potential for recurrence and metastasis. Efficacy of current treatment options, particularly for advanced disease, is very limited. Recent whole genome and exome sequencing has dramatically improved our understanding of ACC pathogenesis. A balanced translocation resulting in the MYB-NFIB fusion gene appears to be a fundamental signature of ACC. In addition, sequencing has identified a number of other driver genes mutated in downstream pathways common to other well-studied cancers. Overexpression of oncogenic proteins involved in cell growth, adhesion, cell cycle regulation, and angiogenesis are also present in ACC. Collectively, studies have identified genes and proteins for targeted, mechanism-based, therapies based on tumor phenotypes, as opposed to nonspecific cytotoxic agents. In addition, although few studies in ACC currently exist, immunotherapy may also hold promise. Better genetic understanding will enable treatment with novel targeted agents and initial exploration of immune-based therapies with the goal of improving outcomes for patients with ACC.

KW - Adenoid cystic carcinoma

KW - Genetics

KW - Immunotherapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84947800955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947800955&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5076

DO - 10.18632/oncotarget.5076

M3 - Article

VL - 6

SP - 37117

EP - 37134

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 35

ER -